Top 5 SARMs Companies: Why This Question Has No Safe or Legitimate Answer

Key takeaways

Why a Ranked List of SARMs Vendors Cannot Be Given Responsibly

Search queries for a "top 5 SARMs companies" typically assume that, as with supplements or medications, some retail brands are more reputable, purer, or safer than others. That assumption does not hold for SARMs. Selective androgen receptor modulators are not approved by the U.S. Food and Drug Administration for any human use. The FDA has stated that products containing SARMs are unapproved drugs that the agency has not reviewed for safety or effectiveness, and it has warned that these products cannot be legally marketed as dietary supplements or drugs.

Because no SARM product sold online is a regulated pharmaceutical or a lawful dietary ingredient, there is no regulatory body, pharmacopeia, or independent certification system that verifies identity, purity, or dose for these products the way the FDA verifies approved drugs or third-party programs verify some supplements. Any "top 5" or "best brand" list found elsewhere online reflects marketing, affiliate relationships, or unverified user reviews rather than independent laboratory or regulatory verification. This page therefore does not rank vendors. Instead, it summarizes what the peer-reviewed and regulatory record actually shows about the companies and products in this space.

The Only Companies Rigorously Developing SARMs Are Pharmaceutical Firms, Not Retail Brands

If the question is which organizations have done legitimate, controlled scientific development of SARM molecules, the answer points to biopharmaceutical companies conducting FDA-regulated clinical trials, not the brands sold on bodybuilding or "research chemical" websites.

GTx, Inc. was founded in Memphis, Tennessee in 1997 and licensed rights to enobosarm (ostarine, also called GTx-024 or MK-2866) from the University of Tennessee Research Foundation. By 2007 enobosarm was in Phase II testing, and GTx signed an exclusive license agreement for its SARM program with Merck & Co. that year; the companies ended the collaboration in 2010. GTx went on to run two identically designed, pivotal Phase III trials of enobosarm, known as POWER-1 and POWER-2, to evaluate prevention and treatment of muscle wasting in patients starting first-line chemotherapy for non-small cell lung cancer. GTx also tested enobosarm in a Phase II trial for stress urinary incontinence in postmenopausal women (the ASTRID trial), which failed to meet its primary endpoint, and in a Phase II trial for estrogen receptor-positive, androgen receptor-positive breast cancer, where the compound met a pre-specified efficacy endpoint in an interim analysis. Despite this development history, enobosarm has not been approved by the FDA for any indication.

Ligand Pharmaceuticals originated the chemistry behind LGD-4033 (ligandrol), and in 2014 Viking Therapeutics licensed the developmental rights and advanced the compound, under the designation VK5211, into mid-to-late-stage trials. In a randomized, double-blind, placebo-controlled Phase II trial in 108 patients recovering from acute hip fracture surgery, VK5211 met its primary endpoint of dose-dependent increases in lean body mass compared with placebo over 12 weeks, with no drug-related serious adverse events reported in that study. An earlier Phase I study examined the safety, pharmacokinetics, and effects of LGD-4033 in healthy young men. As of the most recent published reporting, LGD-4033/VK5211 remains an investigational compound under continued development by Viking Therapeutics and has not completed clinical development or received FDA approval for any use.

Beyond these two better-documented programs, other pharmaceutical companies have at various points explored nonsteroidal androgen receptor ligands in early or preclinical research, though public, verifiable detail on most of these programs is limited. None of this pharmaceutical-grade research constitutes an endorsement of any product sold to consumers under the same or similar chemical names; the retail market operates entirely outside this regulated development pipeline, and no enobosarm- or LGD-4033-labeled product sold online has been through the same manufacturing, purity, or clinical oversight as the compounds studied by GTx or Viking Therapeutics.

What Independent Testing Has Found in Products Sold as SARMs

The clearest evidence on the retail SARMs market comes from independent chemical analyses of products purchased online, and the findings are consistently unfavorable to consumer confidence in any brand.

A widely cited 2017 investigation published in JAMA purchased 44 products marketed as SARMs online, after an initial search identified more than 210 such products for sale, and tested them using chemical analysis procedures used in anti-doping laboratories. The study found that SARMs accounted for only 23 of 44 products tested (52 percent), and in only 18 of the 44 products (41 percent) did the amount of active compound match the label. In 8 products (18 percent) the labeled compound was not detected at all, and 3 products (7 percent) contained the labeled amount but also an unlisted compound; in a further 4 products no active compound was detected at all.

A more recent Italian investigation of SARM products purchased online found that qualitative analysis confirmed the presence of the stated SARM in about 70 percent of samples. In 23 percent of samples the expected SARM was not detected but a different one was found instead, and other undeclared pharmaceutical substances, including tamoxifen, clomifene, testosterone, and tadalafil, were measured in 30 percent of samples, with more than one active substance present together in over 60 percent of samples. Quantitative analysis in that study showed content ranging from 30 to 90 percent of the label claim.

These findings mean that even if a consumer identifies a specific brand as popular or well-reviewed, there is no independent mechanism confirming that any given batch contains the labeled substance at the labeled dose, or that it is free of undeclared contaminants.

FDA Enforcement Actions Show Which Companies Regulators Have Targeted, Not Which Are Safe

Rather than a ranked list of trustworthy vendors, the public record contains a growing list of FDA warning letters against specific SARMs sellers for violating federal drug law. On December 12, 2025, the FDA issued warning letters to multiple companies after reviewing their websites in November 2025, including Titan SARMs LLC (for products marketed as LGD-4033/Ligandrol, RAD-140/Testolone, S-4/Andarine, and YK-11), Atomix LLC (for products including MK-2866), Dynamic Health Group, doing business as SARMS AMERICA, and Pinnacle Professional Research, doing business as Pinnacle Peptides (for S4 Andarine, LGD-4033, and MK-2866).

In each of these letters the FDA determined that the products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act, and that introducing them into interstate commerce violates federal law. In the letter to Atomix LLC, the FDA stated that despite labeling stating "RESEARCH USE ONLY" and "not for human consumption," evidence from the company's product labeling and website established that the products are intended to be drugs for human use.

The FDA's warning letter template for this enforcement wave also states that FDA has safety concerns about products that contain SARMs, that life-threatening reactions including liver toxicity have occurred in people taking products containing SARMs, and that SARMs also have the potential to increase the risk of heart attack and stroke. This enforcement pattern indicates that appearing to be an established or high-volume seller offers no protection from regulatory risk, and it does not correlate with product safety; being targeted by a warning letter simply means a company's website was reviewed and found to violate drug law, not that untargeted sellers are safer.

Legal and Anti-Doping Status of SARMs

In the United States, SARMs are not approved by the FDA for any human use and cannot be legally sold as dietary supplements or drugs. They are not substances a licensed physician can prescribe for any indication.

All SARMs are prohibited at all times, both in and out of competition, for athletes under the World Anti-Doping Code. The U.S. Anti-Doping Agency states that SARMs are listed in the category of "Other Anabolic Agents" under section S1.2 of the WADA Prohibited List, and that all SARMs are prohibited at all times for athletes at every level of competition, including recreational sport. The World Anti-Doping Agency's own Prohibited List names andarine, enobosarm (ostarine), LGD-4033 (ligandrol), RAD140, S-23, and YK-11 as examples in this category, while noting that the list of named examples is not exhaustive. Published research tracking WADA's annual testing figures reports that adverse analytical findings involving SARMs rose from 13 cases in 2013 to 104 cases in 2022, a trend consistent with growing use of these compounds in and around sport.

Health Risks Reported With SARMs Use

Regardless of which company or brand a product is purchased from, FDA statements and peer-reviewed case reports describe a consistent pattern of harm. FDA warning letters state that life-threatening reactions, including liver toxicity, have occurred in people taking products containing SARMs, and that SARMs also have the potential to increase the risk of heart attack and stroke.

Liver injury has drawn particular attention in the medical literature. The NIH's LiverTox resource notes that SARMs were developed with the intent of preserving anabolic effects on muscle and bone while producing fewer and milder androgenic effects on tissues including the prostate, skin, hair, liver, and heart, but that several SARMs available in dietary supplements, whether advertised as such or present as contaminants, have nonetheless been implicated in multiple cases of severe cholestatic jaundice resembling anabolic steroid-induced jaundice. LiverTox also notes that most patients with SARM-related cholestatic jaundice appear to have taken high doses, sometimes combining multiple SARMs simultaneously ("stacking"). Separately, a case report published in World Journal of Clinical Cases described two young men who developed acute cholestatic liver injury, marked by jaundice, elevated bilirubin and bile acids, and biopsy evidence of canalicular bile plugs and ductopenia, after using ligandrol and/or ostarine along with other muscle-building compounds; both recovered over roughly three months after stopping the substances. A more recent case report in Cureus similarly described a patient with SARM-associated acute hepatotoxicity presenting with jaundice, elevated liver enzymes, and a markedly elevated bilirubin level.

These reports do not establish how common serious liver injury is among all SARM users, since adverse events among people using unregulated, unlabeled products are not systematically tracked, but they demonstrate that the marketing claim of tissue-selective activity with reduced off-target effects has not eliminated the risk of clinically significant liver injury in real-world use.

Frequently asked

References